- Curis (CRIS, Financial) to release Q1 2025 financial results on May 6, 2025, at 8:00 a.m. ET.
- Conference call and webcast scheduled for 8:30 a.m. ET on the same day.
- Focus on emavusertib, an IRAK4 inhibitor drug candidate, currently in multiple phases of study.
Curis, Inc. (NASDAQ: CRIS), a biotechnology company, has announced plans to report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Following the results announcement, the management will conduct a conference call and live webcast at 8:30 a.m. ET to discuss the financial results and company developments.
Investors interested in participating in the conference call can dial (800)-836-8184 from within the United States or (646)-357-8785 for international calls. Additionally, a live audio webcast is available through the events & presentations section of the Curis website.
The biotechnology firm is advancing the development of emavusertib (CA-4948), its leading drug candidate, which is an orally available, small molecule IRAK4 inhibitor. Emavusertib is being evaluated in several studies including the Phase 1/2 TakeAim Lymphoma study (CA-4948-101) and the TakeAim Leukemia study (CA-4948-102) for various types of relapsed/refractory cancers. The drug has received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Commission.
A replay of the conference call will be available on Curis's website post-event, providing further access to the financial and operational insights shared during the call.
